Wet Age-Related Macular Degeneration (AMD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035
Wet
Age-Related Macular Degeneration (AMD) Market Outlook
Thelansis’s “Wet Age-Related
Macular Degeneration (AMD) Market Outlook, Epidemiology, Competitive Landscape,
and Market Forecast Report – 2025 To 2035” covers disease overview,
epidemiology, drug utilization, prescription share analysis, competitive
landscape, clinical practice, regulatory landscape, patient share, market
uptake, market forecast, and key market insights under the potential Wet
Age-Related Macular Degeneration (AMD) treatment modalities options for eight
major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Wet
Age-Related Macular Degeneration (AMD) Overview
Wet
Age-Related Macular Degeneration is a vision-threatening condition driven by
choroidal neovascularization from VEGF overexpression, causing subretinal fluid
accumulation and rapid central photoreceptor damage. It presents with
metamorphopsia, central scotoma, and progressive reading difficulty. Optical
coherence tomography and fluorescein angiography confirm diagnosis; fluid
persistence and visual acuity loss reflect severity. High-dose aflibercept and
faricimab, targeting VEGF and Ang-2 pathways, form the modern treatment
standard, with extended dosing intervals improving compliance. The Port
Delivery System offers continuous anti-VEGF release for injection-burdened
patients. Regular OCT monitoring guides retreatment. Early intervention
preserves vision; low vision support underpins quality-of-life care.
Geography coverage:
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and
China)
Insights driven by robust research, including:
- In-depth
interviews with leading KOLs and payers
- Physician
surveys
- RWE analysis
for claims and EHR datasets
- Secondary
research (e.g., peer-reviewed journal articles, third-party research
databases)
Deliverables format and updates*:
- Detailed Report
(PDF)
- Market Forecast
Model (MS Excel-based automated dashboard)
- Epidemiology
(MS Excel; interactive tool)
- Executive
Insights (PowerPoint presentation)
- Others: regular
updates, customizations, consultant support
*As per Thelansis’s policy, we ensure that we include all the recent
updates before releasing the report content and market model.
Salient features of Market Forecast model:
- 10-year market
forecast (2025–2035)
- Bottom-up
patient-based market forecasts validated through the top-down sales
methodology
- Covers
clinically and commercially-relevant patient populations/ line of
therapies
- Annualized
drug-level sales and patient share projections
- Utilizes our
proprietary Epilansis and Analog tool (e.g., drug uptake and erosion)
datasets and conjoint analysis approach
- Detailed
methodology/sources & assumptions
- Graphical and
tabular outputs
- Users can
customize the model based on requirements
Key business questions answered:
- How can drug
development and lifecycle management strategies be optimized across G8
markets (US, EU5, Japan, and China)?
- How large is
the patient population in terms of incidence, prevalence, segments, and
those receiving drug treatments?
- What is the
10-year market outlook for sales and patient share?
- Which events
will have the greatest impact on the market’s trajectory?
- What insights
do interviewed experts provide on current and emerging treatments?
- Which pipeline
products show the most promise, and what is their potential for launch and
future positioning?
- What are the
key unmet needs and KOL expectations for target profiles?
- What key
regulatory and payer requirements must be met to secure drug approval and
favorable market access?
- and more…
Comments
Post a Comment